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vision or loss of upper or lower part of visual ﬁ eld. Most of 
the patients have no progression, but minority of the pa-
tients can notice the worsening of visual impairment. Oph-
thalmoscopically edema of the optic disc is seen. Most of 
the patients have altitudinal, arcuate visual ﬁ eld defects, 
general constriction or diffuse depression of visual ﬁ eld6–8. 
It was thought that there was no accepted treatment for 
this condition. In the past, several types of therapy were 
used in order to reverse the damage and start visual recov-
ery. Therapy with neuroprotective agents such as levodopa, 
optic nerve sheat fenestration, transvitreal optic neurotomy 
were used in treating non-arteritic anterior ischemic optic 
neuropathy were performed, but without signiﬁ cant suc-
cess. Recent publications have suggested that systemic cor-
ticosteroid therapy and intravitreal injections of anti VGF 
therapy could be helpful to improve visual outcome 9–11.
Tha aim of this study is to present 38 patients with 
non-arteritic form of anterior ischemic optic neuropathy 
who were treated with corticosteroid therapy.
Material and Methods
This prospective study included 38 patients with non-
arteritic anterior ischemic optic neuropathy. 18 patiens 
Anterior ischemic optic neuropathy (AION) is damage 
to the optic nerve caused  by insufﬁ cient blood supply. It is 
the result of infarction in the prelaminar portion of the 
optic nerve. This condition may be due to giant cell arteritis 
or not related to such condition. Therefore is generally di-
vided into arteritic and non-arteritic anterior ischemic optic 
neuropathy. The pathogenesis of non-arteritic anterior isch-
emic optic neuropathy is not completely understood1–3. It is 
supposed that occlusion of the short posterior ciliary arter-
ies by thrombi and emboli with temporary hypoperfusion 
of the anterior portion of the optic nerve led to visual dis-
turbances. Patients with crowded or small disc could be the 
risk factor for development such a condition. Hoyt pointed 
out that the optic discs of the patients with non-arteritic 
anterior ischemic optic neuropathy have small disc without 
physiologic cupping. In following studies were suggested 
that this optic disc morphology is the most important risk 
factor4. Many patients with this condition have predispos-
ing factors such a arterial hypertension, diabetes mellitus, 
hyperlipidaemia and arteriosclerosis5. 
Patients with non-arteritic ischemic optic neuropathy 
present with painless blurred vision in one eye, usually 
after awaking. They could feel some discomfort in affected 
eye. Those patients noticed dark shadow which obscurs 
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A B S T R A C T 
Non-arteritic anterior ischemic optic neuropathy is one of the most common conditions affecting the optic nerve in the 
elderly. It may lead to severe visual loss. Typical symptoms are painless impairment of visual function accompanied by 
relative afferent pupillary defect, edema of the optic disc and visual ﬁ eld defects. Aim is to present 38 patients with non-
arteritic anterior ischemic optic neuropathy who were treated with corticosteroid therapy. This prospective study involved 
38 patients, 20 men and 18 women aged 60–75 years who were treated with corticosteroid therapy. The study included 
patients with visual acuity in the affected eye from 0.1 to 0.8 according to Snellen. Every patient underwent clinical ex-
amination, the Octopus 900 perimetry in G program, laboratory testing, while the compressive optic neuropathy was rule 
out with MSCT of the brain and orbits. The most common forms of visual ﬁ eld defect are altitudinal defect and diffuse 
depression. Corticosteroid therapy led to recovery in 65% of patient , in 30% of patients did not change, while the deterio-
ration occurred in 5% of patients.
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were female and 20 male. The mean age was 66.7. The 
diagnosis was established according to clinical criteria: 
painless visual impairment, optic disc edema, visual ﬁ eld 
defects, normal eritrocyte sedimentation level and normal 
level of c-reactive protein10. All patients were treated by 
oral corticosteroid Methylprednisolone 80 mg daily for 5 
days followed by a tapering dose 64 mg for 5 days, 48 mg 
for 5days, 32 mg 5 days, 16 mg for 5 days and 8 mg for 5 
days. The independent ethics committee of the University 
of Zagreb, School of Medicine approved the study which 
was performed according to the tenets of the Helsinki dec-
laration. All patients gave written informed consent. Sub-
jects with established arteritic anterior ischemic optic 
neuropathy, ophthalmologic lesions leading to impaired 
visual function, such as blurred optic media, retinal de-
tachment, glaucoma, inﬂ ammatory changes, degenerative 
chorioretinal changes, diabetic retinopathy, etc., were ex-
cluded. Patients with refraction error greater than 3 diop-
ters were also excluded. Each examination began with 
taking history data, followed by ophthalmologic examina-
tion, and visual ﬁ eld testing by automated Octopus 900 
perimetry. Ophthalmologic examination is consisted of 
visual acuity testing, biomicroscopy, aplanation tonometry 
and indirect ophthalmoscopy. Visual acuity was assessed 
by the subjective method using standard optotypes accord-
ing to Snellen at 6-m distance. Vision ﬁ eld was tested on 
Octopus 900 perimeter using G program. On visual ﬁ eld 
testing, the parameters of mean defect (MD) and the pat-
tern of visual ﬁ eld defects were analyzed. Visual ﬁ eld de-
fects were categorised according to the pattern as follows:
1. arcuate defect
2. altitudinal defect
3. diffuse depression
4. central island of visual ﬁ eld
5. other defects
Clinical examination and Octopus perimetry were per-
formed at admition and 6 month after the cesation of 
therapy. We analysed visual acuity (VA) and the values of 
mean defect (MD).
Statistical methods
For all the analyzed variables descriptive statistics was 
made. The level of signiﬁ cance of 5% in all tests was con-
sidered statistically signiﬁ cant. In order to show that 
there were no differences between age for both sexes we 
used Student`s T test. Differences between the VA and MD 
before and after treatment for both sexes we tested using 
repeated measure analysis of variance. A statistical anal-
ysis as well as graphics were made using STATISTICA.
Results
At the time of initial examination, mean visual acuity 
was. Visual acuity from 0.1 to 0.3 according to Snellen was 
found in 19 patients, visual acuity form 0.4 to 0.7 had 18 
patients, and one patient had visual acuity 0.8 according 
to Snellen. In all patient edema of the optic disc was vis-
ible with indirect ophthalmoscopy. Mean MD was 11.8 
(Table 1). The most common visual ﬁ eld defects were alti-
tudinal defect, which was found in 17 patients, and diffuse 
depression, which was found in 16 patients. Central island 
of visual ﬁ eld had 3 patient and other forms of defect 2 
patients. 
Every patient underwent control clinical examination 
and testing of the visual ﬁ eld six months after the cessa-
tion of therapy. On control clinical examination was found 
improvement of visual acuity as well as improvement of 
visual ﬁ eld. 
The results of repeated measure ANOVA show that 
there is no statistically signiﬁ cant difference in VA and 
MD for both sexes. For measurements before and after 
there was a statistically signiﬁ cant difference. The inter-
action was not statistically signiﬁ cant, indicating that the 
changes behave the same in both sexes (Table 2).
On control examination mean visual acuity was 0.39 
and mean MD was 10.1. Figure 1 is showing the compari-
sons of the result of visual acuity testing at initial and con-
trol examination. Figure 2 is showing the comparison of 
visual ﬁ led testing between initial and control examination. 
TABLE 1
DESCRIPTIVE STATISTICS
X SD X SD
VA0 VA1
female   0.27 0.09   0.38 0.16
male   0.27 0.11   0.40 0.07
MD0 MD1
female 11.80 2.10 10.01 1.93
male 11.76 1.93 10.18 1.13
VA0 – visual acuity at initial examination; VA1 – visual auity at 
control examination; MD0 – mean defect at initial examination; 
MD1 – mean defect at control examination
TABLE 2
RESULTS OF REPEATED MEASURE ANOVA
 VA MD
 MS F p MS F p
Gender 0.00   0.15   0.704   0.05   0.01   0.923
Error a 0.02     5.49   
Time 0.18 19.68 <0.001 35.57 35.07 <0.001
Time*gender 0.00   0.17   0.681   0.13   0.13   0.720
Error b 0.01     1.01   
VA – visual acuity; MD – mean defect
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Discussion
In this study we have presented the results of clinical 
evaluation and the results of therapy in 38 patients with 
non-arteritic anterior ischemic optic neuropathy. Mean 
visual acuity according to Snellen was 0.27. Octopus 900 
perimetry in G program showed diffuse depression and 
altitudinal defects to be the most common visual ﬁ eld de-
fect. Hayreh suggested that perimetry  is the most impor-
tant visual function test to detect visual loss, since some 
patients with such a condition had normal visual acuity. 
He also noted that a combination of a relative inferior al-
titudinal defect with absolute inferior nasal defect is most 
common visual defect pattern10. In our study most of the 
patients had altitudinal defects and diffuse depression. 
This difference could be due to smaller number of patients 
and different methods of visual ﬁ eld testing. 
Hayreh noted that optic disc edema is main clinical ﬁ nd-
ing at the onset of visual loss, which resolves spontaneusly10. 
In all our patients we have found optic disc edema at initial 
examination. 4 patients had a few splinter hemorrhages on 
the optic disc. 6 months later edema has resolved and pallor 
of optic disc was seen on control examination. 
The therapy of this condition is still controversial. In 
the past, many investigators tried various therapies to 
improve visual outcome in patient with non-arteritic an-
terior ischemic optic neuropathy. Multiple medical thera-
pies were used, such as brimonidin, levodopa, anticoagula-
tion, dyphenylhydantoin and norepinephrine. But they 
had no beneﬁ t on visual function4. Hyperbaric oxygen and 
optic nerve sheet decompression also had no beneﬁ t. It was 
reported that the use of intravitreal injection of triam-
cinolone resulted with visual function improvement. They 
suggested that intravitreal applied corticosteroids reduced 
optic disc edema and got better visual function4,11. But we 
will have to wait for more reports and clinical studies in 
order to conclude whether this therapy is successful. So-
heilian and coworkers reported that transvitreal optic 
neurotomy improved visual function in six out of seven 
patients with non-arteritic anterior ischemic optic neu-
ropathy12. More recently Hayreh and Zimmerman report-
ed the treatment with systemic corticosteroid therapy. 
This study included 613 consecutive patients with non-
arteritic anterior ischemic optic neuropathy. 312 patients 
were treated with oral prednisone. On the other hand 301 
patients decided no treatment. Every patient underwent 
ophthalmic evaluation and Goldmann perimetry. They 
concluded that patients treated with corticosteroid thera-
py have higher probability of recovery of visual acuity and 
visual ﬁ eld. In our study we have treated 38 patients with 
oral corticosteroid Methylprednisolone 80 mg daily for 5 
days followed by tapering doses. It is supposed that corti-
costeroid therapy relievs the pressure on the axons during 
the acute phase with edema of the optic disc, which could 
prevent further damage to the optic nerve. 
Since perimetry is one of the most important test of 
visual function, we chose Octopus 900 perimetry in G pro-
gram besides visual acuity testing to be the major method 
to follow the results of therapy. We have found statisti-
cally signiﬁ cant difference between mean visual acuity 
and mean MD prior and after the therapy. On the other 
hand, other authors have not supported systemic cortico-
steroid therapy in patients with non-arteritic anterior 
ischemic optic neuropathy, since this therapy is not based 
on any level I evidence and it is potentialy dangerous15. 
In conclusion, although we found improvement of vi-
sual function in patients with non-arteritic anterior ishae-
mic optic neuropathy treated with systemic corticoste-
roids, this study should complement with higher number 
of patients and with control group of patients with non-
arteritic patient were treated with no systemic corticoste-
roids.
Fig. 1. Comparison of results of visual acuity testing between 
initial and control examination. VA 01 – results of visual acuity 
testing at initial examination, VA 02 – results of visual acuity 
tesing at control examination.
Fig. 2. Comparison of results of visual fi eld testing between 
initial and control examination. MD 01 – results of mean defect 
of visual fi eld testing at initial examination,  MD 02 – results of 
mean defect of visual fi eld testing at control examination.
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KORTIKOSTEROIDI U LIJEČENJU BOLESNIKA S NEARTERITIČKOM PREDNJOM ISHEMIČKOM 
OPTIČKOM NEUROPATIJOM
S A Ž E T A K
Autori prikazuju 38 bolesnika s nearteritičkom prednjom ishemičkom optičkom neuropatijom koji su liječeni kor-
tikosteroidima. U ovom prospektivno istraživanju sudjelovalo je 38 ispitanika, 20 muškaraca i 18 žena u dobi 60 do 75 
godina, koji su liječeni kortikosteroidima. U istraživanje su uključeni bolesnici s vidnom oštrinom na zahvaćenom oku 
od 0,1 do 0,8 prema Snellenu. Svi su klinički pregledani uz Octopus 900 perimetriju u G programu i laboratorijsku 
opservaciju, dok se kompresivna optička neuropatija isključila MSCTom mozga i orbita. Najčešći oblici oštećenja vidnog 
polja bili su altitudinalni defekt i difuzna depresija mrežnične osjetljivosti. Kortikosteroidna terapija dovela je do opor-
avka u 65% bolesnika, u 30% bolesnika nije bilo promjena, dok je pogoršanje nastupilo u 5% bolesnika.
